Alcon intends to acquire Ivantis, the developer and manufacturer of the Hydrus microstent, according to a company press release.
Alcon will pay $475 million upfront and may make additional contingent payments depending on regulatory and commercial milestones, the release said.
“Glaucoma is the second-largest cause of blindness after cataracts, impacting more than 75 million people globally, with significant unmet patient need. This transaction will allow us to add a uniquely effective product into our glaucoma portfolio around the world,” David Endicott, CEO of Alcon, said in the